Non-Stimulant ADHD Access Landscape (2026): Simtriyo NDSRI & Generic Economics

The market access landscape for attention-deficit/hyperactivity disorder (ADHD) reached a major therapeutic milestone on July 24, 2026, when the FDA approved Otsuka Pharmaceutical’s Simtriyo (centanafadine). As a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor (NDSRI), centanafadine introduces the first novel mechanism of action for ADHD in years.

However, bringing a new non-stimulant brand to market requires navigating a complex, highly stratified commercial environment. Formularies are anchored by deeply discounted generic non-stimulants (atomoxetine, guanfacine ER, and clonidine ER) while patient demand is surging due to persistent supply shortages affecting Schedule II stimulants like methylphenidate and amphetamine salts. Furthermore, Simtriyo faces a unique regulatory gate: despite securing FDA approval, commercial availability remains paused pending final controlled-substance scheduling by the U.S. Drug Enforcement Administration (DEA).

This post-approval access analysis examines how Simtriyo reshapes the non-stimulant ADHD therapeutic class, evaluating mechanism tiers, Orange Book generic density, NADAC pricing benchmarks, DEA scheduling friction, and payer formulary positioning.

Direct Answer: Class Architecture and Commercial Landscape

Following the approval of Simtriyo, the non-stimulant ADHD treatment landscape spans four distinct pharmacologic mechanism tiers across five major molecule families:

1. Triple Reuptake Inhibitor (NDSRI): Centanafadine (Simtriyo) — Approved July 24, 2026 (Otsuka) for adults and pediatric patients (aged ≥6 years, weighing ≥20 kg). Supported by four pivotal Phase 3 clinical trials demonstrating statistically significant reductions in ADHD symptom scores (ADHD-RS-5 and AISRS). Carries boxed warnings for pediatric suicidal ideation/behaviors and risk of abuse, misuse, and addiction. Commercial availability is pending DEA scheduling later in 2026.
2. Selective Norepinephrine Reuptake Inhibitors (Selective NRIs):
   • Atomoxetine (Strattera) — First FDA-approved non-stimulant (2002). Deeply generic with 56 ANDA product listings in the FDA Orange Book. Highly accessible with CMS NADAC acquisition costs ranging from **$0.35 to $0.58 per capsule**.
   • Viloxazine (Qelbree) — Approved in 2021 (Supernus). Brand-only with 0 generic ANDAs. Operates as a premium-priced brand specialty in commercial formularies.
3. Alpha-2A Adrenergic Agonists:
   • Guanfacine ER (Intuniv) — Approved in 2009. Highly generic with 76 ANDA product listings. Exceptionally cheap acquisition cost with NADAC ranging from **$0.14 to $0.22 per tablet**.
   • Clonidine ER (Kapvay) — Approved in 2010. Deeply generic with ~103 clonidine ingredient ANDA listings (spanning IR and ER formulations). Lowest-cost non-stimulant floor with IR NADAC below $0.04 per tablet.

Non-Stimulant ADHD Landscape: Generic Floor vs. Brand Specialties
┌───────────────────────────────────────────────────────────┐
│ Brand Specialties (Pending / Active Premium Tier)          │
│  • Simtriyo (centanafadine) - NDSRI (DEA Scheduling)      │
│  • Qelbree (viloxazine) - Selective NRI (Brand Only)      │
├───────────────────────────────────────────────────────────┤
│ Generic Non-Stimulant Floor (Step 1 Preferred Tier)       │
│  • Atomoxetine (Strattera) - ~56 ANDAs (NADAC ~$0.35-0.58)│
│  • Guanfacine ER (Intuniv) - ~76 ANDAs (NADAC ~$0.14-0.22)│
│  • Clonidine ER (Kapvay) - ~103 ANDAs (NADAC <$0.04)      │
└───────────────────────────────────────────────────────────┘

For historical perspective on centanafadine's pre-approval NDA submission and regulatory timeline, refer to our prior centanafadine PDUFA preview.

How Non-Stimulant ADHD Medication Classes Differ by Mechanism and Neurochemistry

Understanding the therapeutic distinctions across non-stimulant classes is essential for market-access leads constructing prior authorization (PA) criteria and step-therapy algorithms.

Neurochemical Binding Profiles Across Non-Stimulant Classes
┌───────────────────────┐  ┌───────────────────────┐  ┌───────────────────────┐
│ Centanafadine (NDSRI) │  │ Atomoxetine / Qelbree │  │ Guanfacine / Clonidine│
├───────────────────────┤  ├───────────────────────┤  ├───────────────────────┤
│ • NET Inhibition      │  │ • Selective NET       │  │ • Post-synaptic       │
│ • DAT Inhibition      │  │   Inhibition          │  │   Alpha-2A Adrenergic │
│ • SERT Inhibition     │  │ • Minimal DAT/SERT    │  │   Receptor Agonism    │
│ NET-Preferring       │  │ Single Monoamine      │  │ Non-monoamine         │
│ Triple Modulation    │  │ Modulation            │  │ Signal Enhancement    │
└───────────────────────┘  └───────────────────────┘  └───────────────────────┘

1. Norepinephrine-Dopamine-Serotonin Reuptake Inhibitors (NDSRIs)

Centanafadine (Simtriyo) acts as a triple reuptake inhibitor, blocking the reuptake transporters for norepinephrine (NET), dopamine (DAT), and serotonin (SERT), but with a clear norepinephrine preference.

In pre-clinical in vitro binding assays, centanafadine exhibits IC50 values of approximately 6 nM for NET, 38 nM for DAT, and 83 nM for SERT—roughly 6-fold stronger for norepinephrine than dopamine and 14-fold stronger than serotonin. In a phase 1 PET occupancy study, centanafadine produced high NET occupancy but only moderate DAT and SERT occupancy at the 400 mg/day dose. That residual dopamine engagement is pharmacologically meaningful: it underpins the label's boxed warning for abuse, misuse, and addiction, even though centanafadine is not a Schedule II amphetamine.

2. Selective Norepinephrine Reuptake Inhibitors (Selective NRIs)

Atomoxetine and viloxazine selectively inhibit NET, boosting prefrontal cortex concentrations of norepinephrine and secondary dopamine (where DAT density is sparse and NET handles dopamine reuptake).

However, they exert minimal activity at SERT. Atomoxetine requires 4 to 6 weeks of continuous daily administration to achieve full therapeutic effect, whereas viloxazine displays a slightly faster onset profile (2 to 4 weeks).

3. Alpha-2A Adrenergic Receptor Agonists

Guanfacine ER and clonidine ER do not inhibit monoamine reuptake. Instead, they directly stimulate post-synaptic alpha-2A adrenergic receptors in the prefrontal cortex, strengthening dendritic signal transduction and improving working memory and impulse control.

Alpha-2 agonists are frequently prescribed as monotherapy or adjunctive therapy alongside stimulants, particularly in pediatric patients with co-morbid sleep disturbances, tics, or oppositional symptoms.

Clinical Trial Evidence: Pivotal Phase 3 Program for Simtriyo (centanafadine)

The FDA approval of Simtriyo was grounded in a comprehensive Phase 3 clinical development program comprising four randomized, double-blind, placebo-controlled trials: one in children, one in adolescents, and two in adults. In all four, centanafadine demonstrated statistically significant improvements in ADHD symptoms compared with placebo.

A regulatory nuance worth flagging for formulary reviewers: the two adult studies used an earlier twice-daily centanafadine formulation, and the FDA bridged those results to the marketed once-daily 210 mg and 280 mg capsules on the basis that no efficacy differences are expected. No adult efficacy trial was run on the marketed capsule itself; the pediatric and adolescent studies, by contrast, used the marketed formulation. This bridging assumption—not a head-to-head capsule trial—is what supports the adult indication.

Primary Endpoint Reductions Across Phase 3 Program
┌───────────────────────────────────────────────────────────┐
│ Pediatric Phase 3 Program (ADHD-RS-5 Total Score)         │
│  - Statistically significant vs. placebo in both trials   │
├───────────────────────────────────────────────────────────┤
│ Adult Phase 3 Program (AISRS Total Score)                 │
│  - Statistically significant vs. placebo in both trials   │
└───────────────────────────────────────────────────────────┘

Across all four trials, centanafadine demonstrated a consistent safety and tolerability profile. The most common treatment-emergent adverse events (TEAEs) reported with an incidence ≥5% and at least twice the rate of placebo included:

• Pediatric Patients (Ages 6–17): Rash, decreased appetite, nausea, headache, and abdominal pain.
• Adult Patients (Ages 18–55): Headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea.

Crucially, blood pressure and heart rate elevations were generally mild-to-moderate and self-limiting, presenting a manageable cardiovascular risk profile relative to amphetamines.

Dosing, Titration, Metabolism, and Differentiating Pharmacokinetics

To evaluate clinical positioning and pharmacy substitution rules, P&T committees analyze the pharmacokinetic and metabolic properties of each non-stimulant agent.

1. Centanafadine (Simtriyo) Dosing & Metabolism

Centanafadine is supplied as a once-daily (QD) extended-release oral capsule (140 mg, 210 mg, 280 mg) taken in the morning. Dosing is weight-tiered in pediatric patients: children 6–12 years weighing ≥20 kg receive 140, 210, or 280 mg by weight band; adolescents 13–17 years receive 280 mg once daily; and adults start at 210 mg once daily, titratable to a maximum of 280 mg. Centanafadine is primarily metabolized by monoamine oxidase A (MAO-A), with an elimination half-life of about 5.2 hours, and is therefore contraindicated with—or within 14 days of stopping—MAO inhibitors. Because clearance does not route through CYP2D6, centanafadine avoids the poor-metabolizer exposure swings that complicate atomoxetine, though serotonergic and pressor interactions still warrant review.

2. Atomoxetine (Strattera) CYP2D6 Polymorphism Friction

Atomoxetine is heavily metabolized by hepatic cytochrome P450 2D6 (CYP2D6). Approximately 7% of Caucasians and 2% of African Americans are CYP2D6 poor metabolizers (PMs). In poor metabolizers, atomoxetine AUC is 10-fold higher and peak blood concentrations are 5-fold higher compared to extensive metabolizers (EMs), resulting in significantly higher rates of adverse events (dry mouth, constipation, urinary retention, erectile dysfunction, and elevated heart rate). Payers and clinicians must adjust dosing downward in poor metabolizers or when co-administered with strong CYP2D6 inhibitors like fluoxetine or paroxetine.

3. Viloxazine (Qelbree) CYP1A2 Inhibition Risk

Viloxazine is a strong inhibitor of CYP1A2. Co-administration of Qelbree with CYP1A2 substrates (such as theophylline, tizanidine, or duloxetine) is contraindicated or requires major dose reductions. This metabolic constraint creates prior authorization friction for adult patients taking concurrent psychiatric or neuromuscular medications.

4. Alpha-2 Agonist Rebound and Tapering Rules

Guanfacine ER and clonidine ER require mandatory gradual dose titration during initiation and step-down tapering during discontinuation. Abrupt cessation of clonidine or guanfacine can trigger severe rebound hypertension, tachycardia, and encephalopathy. In contrast, centanafadine and atomoxetine do not produce rebound hypertension upon abrupt discontinuation.

What Is the Generic-vs-Brand Economic Landscape (Orange Book ANDAs and NADAC)?

The commercial viability of any new non-stimulant entrant is heavily constrained by the generic structure of the existing market. Analysis of the FDA Orange Book product database and CMS National Average Drug Acquisition Cost (NADAC) data reveals a steep economic divide.

Generic Density in FDA Orange Book (Ingredient-Level ANDAs)
Atomoxetine (Strattera) │ ████████████████████████ 56
Guanfacine (Intuniv)   │ ████████████████████████████████ 76
Clonidine (Kapvay)     │ ████████████████████████████████████████ 103
Viloxazine (Qelbree)   │ 0 (Brand Only)
Centanafadine (Simtriyo)│ 0 (Brand New / Pending Launch)

1. Generic Non-Stimulant Floor

The FDA Orange Book registers extensive generic competition across legacy non-stimulants:

• Atomoxetine HCl: ~56 ANDA product listings across multiple dosage strengths (10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg). CMS NADAC pricing benchmarks show acquisition costs ranging from about $0.35 to $0.58 per capsule across strengths, establishing a baseline monthly therapy cost of roughly $11 to $17.
• Guanfacine ER: ~76 ANDA product listings across 1 mg, 2 mg, 3 mg, and 4 mg extended-release tablets. NADAC pricing for the ER tablets ranges from about $0.14 to $0.22 per tablet, establishing a monthly therapy cost under $7.
• Clonidine HCl: ~103 ANDA listings spanning immediate-release and extended-release formulations. Immediate-release clonidine NADAC costs fall below $0.04 per tablet (0.1 mg tablets around $0.025).

(Note: Ingredient-level Orange Book ANDA counts reflect all approved generic drug product listings across dosage forms, routes, and strength variations recorded in the FDA database).

2. Brand Specialty Tier

In sharp contrast to the generic floor, viloxazine (Qelbree) operates with zero generic competition. Because Qelbree carries a Wholesale Acquisition Cost (WAC) exceeding $350 to $400 per month and is absent from generic NADAC tables, commercial payers routinely place Qelbree on Tier 3 (Non-Preferred Brand) or require step therapy through generic atomoxetine or guanfacine ER.

Otsuka's Simtriyo enters the market into this exact structural divide. Lacking generic competition, Simtriyo will launch as a premium brand. PBMs will scrutinize whether its triple-reuptake NDSRI mechanism delivers sufficient clinical differentiation over $0.35/day generic atomoxetine to justify a Tier 2 or Tier 3 formulary placement.

Why Is DEA Scheduling the Defining Access Wrinkle for Simtriyo's Launch?

The most critical operational bottleneck facing Simtriyo's commercial entry is the distinction between FDA approval and commercial availability.

On July 24, 2026, the FDA granted approval for Simtriyo's New Drug Application (NDA). However, because centanafadine exhibits affinity for dopamine and serotonin transporters, the FDA evaluated its potential for abuse and dependence during review. As required by the Controlled Substances Act (CSA) for new molecular entities with potential central nervous system activity, final commercial distribution cannot occur until the U.S. DEA issues a final controlled-substance scheduling decision.

Simtriyo Launch & Access Timeline: Approval to Pharmacy Distribution
┌───────────────────────────────────────────────────────────┐
│ Step 1: FDA NDA Approval Granted (July 24, 2026)          │
│  - Label, Boxed Warnings, and Endpoints Established      │
└─────────────────────────────┬─────────────────────────────┘
                              ▼
┌───────────────────────────────────────────────────────────┐
│ Step 2: DEA Controlled Substance Scheduling (Pending 2026)│
│  - DEA reviews HHS scheduling recommendation              │
│  - Final Order published in Federal Register (90-day window)│
└─────────────────────────────┬─────────────────────────────┘
                              ▼
┌───────────────────────────────────────────────────────────┐
│ Step 3: Commercial Distribution & Pharmacy Availability   │
│  - Otsuka ships product to wholesalers (Amerisource, McK) │
│  - NDC activated in pharmacy clearinghouses & PBM systems │
└─────────────────────────────┬─────────────────────────────┘
                              ▼
┌───────────────────────────────────────────────────────────┐
│ Step 4: PBM & Health Plan Formulary Placement             │
│  - P&T Committees review for Tier placement / PA criteria │
└─────────────────────────────┴─────────────────────────────┘

Implications of Pending DEA Scheduling:

1. Commercial Availability Lag: Historical precedents (such as Vyvanse, Sunosi, Dayvigo, and Qelbree—which was ultimately non-controlled) show that DEA scheduling decisions for CNS drugs typically take 60 to 90 days following FDA approval. Otsuka explicitly noted in its approval announcement that Simtriyo is expected to become commercially available later in 2026 following DEA scheduling.
2. Scheduling Designation Risk: If the DEA assigns centanafadine to Schedule IV or V, or determines it to be non-controlled (similar to Qelbree), it will enjoy a massive commercial advantage over Schedule II stimulants. If it receives a Schedule IV designation, prescribers can issue 6-month refills with electronic prescribing, bypassing the rigid monthly paper/electronic script rules mandatory for Schedule II amphetamines.
3. PBM Adjudication Block: Pharmacy Benefit Managers (PBMs) cannot add an NDC to active drug files or establish prior authorization rules until the DEA scheduling code is finalized and commercial inventory enters the supply chain.

What Are the Boxed-Warning and Safety Profiles Across the Non-Stimulant Class?

Safety labeling exerts a powerful influence on payer prior authorization criteria and physician prescribing patterns. The non-stimulant class features distinct safety warnings that govern clinical placement:

Boxed Warning Comparison Across Non-Stimulants
┌──────────────────────────────┬──────────────────────────────┐
│ Simtriyo (centanafadine)     │ Qelbree (viloxazine)         │
├──────────────────────────────┼──────────────────────────────┤
│ 1. Pediatric Suicidal        │ 1. Pediatric Suicidal        │
│    Ideation & Behaviors      │    Ideation & Behaviors      │
│ 2. Risk of Abuse, Misuse,    │                              │
│    and Addiction             │                              │
├──────────────────────────────┴──────────────────────────────┤
│ Strattera (atomoxetine)                                      │
├──────────────────────────────────────────────────────────────┤
│ 1. Pediatric Suicidal Ideation & Behaviors                   │
└──────────────────────────────────────────────────────────────┘

1. Simtriyo (centanafadine) Boxed Warnings & Labeling

FDA-approved labeling for Simtriyo includes two explicit Boxed Warnings:

• Suicidal Ideation and Behaviors in Pediatric Patients: Higher risk of suicidal thoughts and behaviors in children and adolescents aged 6 to 17 years. Patients must be monitored closely for clinical worsening and emergence of suicidal thoughts.
• Abuse, Misuse, and Addiction: Due to its monoamine reuptake inhibition profile (including DAT activity), prescribers must assess the risk of abuse prior to prescribing and monitor for signs of misuse or addiction throughout therapy.

Additional warnings cover blood pressure and heart rate increases, activation of mania/hypomania, and ocular effects (angle-closure glaucoma).

2. Atomoxetine and Qelbree Suicidality Boxed Warnings

Both atomoxetine (Strattera) and viloxazine (Qelbree) carry a Boxed Warning for suicidal ideation in children and adolescents. This warning requires prescribers to counsel families on behavioral monitoring during initial titration and dose adjustments.

3. Guanfacine ER and Clonidine ER Cardiovascular Warnings

Alpha-2 agonists carry no boxed warnings for suicidality or abuse. Instead, their warnings focus on hypotension, bradycardia, and somnolence. Abrupt discontinuation can trigger rebound hypertension, requiring gradual tapering when discontinuing therapy.

Post-marketing safety signals and real-world adverse event trends across all ADHD drug classes are tracked in our study of ADHD medication FAERS adverse events by the numbers.

Medicaid vs. Commercial vs. Medicare Channel Dynamics and Telehealth Rules

Formulary management for ADHD drugs varies substantially across healthcare coverage channels:

• Medicaid (Pediatric Focus): State Medicaid programs cover a large proportion of pediatric ADHD patients. Medicaid Preferred Drug Lists (PDLs) mandate aggressive step therapy, requiring pediatric patients to trial generic atomoxetine or generic guanfacine ER before approving brand-name agents like Qelbree or Simtriyo. Supplemental rebate negotiations will determine Simtriyo's access on state PDLs.
• Commercial PBMs (Pediatric & Adult Focus): Commercial plans account for the majority of adult ADHD prescriptions. PBMs typically utilize open or custom preferred tiers. Given the high demand for adult ADHD treatment during stimulant shortages, commercial PBMs may offer preferred access if Otsuka provides competitive net pricing via manufacturer rebates.
• Medicare Part D (Adult & Senior Focus): Medicare Part D historically restricts coverage for ADHD medications, as adult ADHD was not traditionally recognized under CMS basic benefit designs. However, for beneficiaries with documented adult ADHD or off-label neurological indications, Part D plans require prior authorization establishing medical necessity.
• Telehealth Prescribing Rules: Under Ryan Haight Act provisions, prescribing Schedule II stimulants via telehealth requires an in-person medical evaluation (subject to DEA temporary flexibilities). Non-controlled or lower-schedule (Schedule IV/V) non-stimulants enjoy far broader telehealth prescribing latitude, allowing digital health platforms to prescribe atomoxetine, Qelbree, or centanafadine without in-person visit barriers.

Access Mechanics Across Coverage Channels
┌──────────────────────────────┬──────────────────────────────┐
│ State Medicaid Programs      │ Commercial PBM Formularies   │
├──────────────────────────────┼──────────────────────────────┤
│ • Strict PDL Step-Therapy    │ • Tier 2 / Tier 3 Placement  │
│ • Supplemental Rebate Gate   │ • PA / Shortage Exceptions   │
│ • High Pediatric Volume      │ • High Adult / Worker Volume │
└──────────────────────────────┴──────────────────────────────┘

How Should Payers Position Non-Stimulants Relative to Schedule II Stimulants During the Shortage?

The commercial context for Simtriyo's launch is profoundly shaped by ongoing supply disruptions affecting Schedule II stimulants.

According to CDC data, approximately 7 million US children (11.4%) and 15.5 million US adults (6.0%) have received an ADHD diagnosis. Since late 2022, persistent supply-chain bottlenecks, DEA bulk manufacturing quotas, and telehealth demand surges have created chronic shortages of Adderall (mixed amphetamine salts), Vyvanse (lisdexamfetamine), and generic methylphenidate ER.

Payer Formulary Decision Matrix: Stimulant Shortage Adaptation
┌───────────────────────────────────────────────────────────┐
│ Active Stimulant Supply Shortage (Schedule II Quota Cap) │
└─────────────────────────────┬─────────────────────────────┘
                              ▼
┌───────────────────────────────────────────────────────────┐
│ Payer Non-Stimulant Access Positioning Strategy           │
├──────────────────────────────┬────────────────────────────┤
│ Tier 1: Generic Non-Stim     │ Tier 2/3: Brand Non-Stim   │
│ • Atomoxetine (Strattera)    │ • Qelbree (viloxazine)     │
│ • Guanfacine ER (Intuniv)    │ • Simtriyo (centanafadine) │
│  └── Automatic Approval      │  └── PA / Step-through     │
│      when Stimulants OOS     │      Generic Non-Stimulant  │
└──────────────────────────────┴────────────────────────────┘

Payer Formulary Management Strategies:

1. Shortage-Driven Step-Therapy Exceptions: Health plans traditionally required patients to fail at least one Schedule II stimulant before granting coverage for brand-name non-stimulants. However, during documented stimulant shortages, major PBMs (such as Express Scripts and Caremark) have implemented automated pharmacy claim edits allowing immediate step-through to non-stimulants when stimulant NDCs return "Out of Stock" (OOS) rejections.
2. Formulary Placement for Simtriyo: Given the presence of generic atomoxetine ($0.35/day), PBM Pharmacy & Therapeutics (P&T) committees will likely place Simtriyo on Tier 3 (Non-Preferred Brand) or Tier 2 (Preferred Brand with Prior Authorization). Payers will require prior authorization confirming:
   • Diagnosis of ADHD in patients aged ≥6 years (weighing ≥20 kg).
   • Trial and failure, contraindication, or documented shortage-related unavailability of generic atomoxetine or guanfacine ER.
   • Baseline cardiovascular evaluation and monitoring plan for suicidal ideation and abuse.

For an in-depth operational review of stimulant supply chain constraints, DEA quota allocation mechanics, and patient access dynamics, consult our analysis of the ADHD stimulant shortage.

Frequently Asked Questions (FAQ)

Is centanafadine (Simtriyo) a controlled substance, and when will it be commercially available?

While FDA approved Simtriyo on July 24, 2026, the drug is not yet commercially available. Because centanafadine acts on central monoamine transporters (including dopamine), its final controlled-substance scheduling status must be established by the U.S. DEA under the Controlled Substances Act.

Otsuka expects commercial launch later in 2026 following publication of the DEA's final scheduling order in the Federal Register.

Which non-stimulant ADHD medications are generic, and what do they cost at NADAC?

Three major non-stimulant molecules are available as low-cost generics:

• Atomoxetine (Strattera): 56 generic ANDAs; CMS NADAC acquisition cost is **$0.35 to $0.58 per capsule**.
• Guanfacine ER (Intuniv): 76 generic ANDAs; NADAC cost is **$0.14 to $0.22 per tablet**.
• Clonidine (Kapvay / IR): ~103 generic ANDAs; immediate-release NADAC cost is <$0.04 per tablet.

In contrast, viloxazine (Qelbree) and centanafadine (Simtriyo) are brand-only medications with zero generic competition.

How does Qelbree (viloxazine) differ from generic Strattera (atomoxetine) on formulary?

Both Qelbree and Strattera act as selective norepinephrine reuptake inhibitors (NRIs) and carry Boxed Warnings for pediatric suicidal ideation. However, Strattera is deeply generic (~56 ANDAs) with a monthly acquisition cost under $20, whereas Qelbree is a brand-only product with a monthly WAC exceeding $350.

Consequently, health plans place generic atomoxetine on Tier 1 (Preferred Generic) and position Qelbree on Tier 3 or behind prior authorization step-therapy rules requiring prior trial of generic atomoxetine or guanfacine.

Sources

1. Otsuka Pharmaceutical Co., Ltd.. Otsuka Receives FDA Approval for First-in-Class SIMTRIYO (centanafadine) for Attention-Deficit/Hyperactivity Disorder (ADHD). Official Press Release, Published July 24, 2026. Available at: https://www.otsuka-us.com/otsuka-shares-fda-review-update-for-centanafadine
2. U.S. Food and Drug Administration (FDA). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Data Snapshot: June 10, 2026. Available at: https://www.accessdata.fda.gov/scripts/cder/ob/
3. Centers for Medicare & Medicaid Services (CMS). National Average Drug Acquisition Cost (NADAC) Weekly File. Data Snapshot: July 8, 2026. Available at: https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program-nadac
4. HCP Live / Psychiatric Times. FDA Approves Centanafadine for ADHD in Adults and Children Aged 6 Years and Older. Clinical Regulatory Summary, Published July 2026. Available at: https://www.hcplive.com/view/fda-approves-centanafadine-adhd-adults-children-6-years
5. Drugs.com. Simtriyo (centanafadine) Approval History & NDA Timeline. Regulatory Database, Updated July 2026. Available at: https://www.drugs.com/history/simtriyo.html